PRF Technologies Ltd. (Nasdaq: PRFX) ("PRF" or the "Company"), a clinical-stage specialty pharmaceutical company focused on reformulating established therapeutics for post-operative pain management, today announced expanded results from its previously reported preclinical study directly comparing its lead product candidate, PRF-110, to ZYNRELEF® (bupivacaine and meloxicam extended-release solution), an approved extended-release product used as a benchmark in the study. The expanded results characterize the pharmacokinetic (PK) and tissue-distribution properties of PRF-110 alongside the analgesic efficacy data previously announced.

PRF-110 is a proprietary, oil-based, viscous, clear extended-release formulation of ropivacaine designed to be deposited directly into the surgical wound bed prior to closure. The product candidate is being developed to provide prolonged local analgesia following surgery through a single administration at the surgical site, with the goal of reducing the use of opioids for post-surgical pain.